Mayor Sylvester Turner, TMC CEO Bill McKeon, Governor Greg Abbott, and others gave their remarks at the TMC3 Collaborative Building opening. Photo by Natalie Harms

For nearly a decade, the Texas Medical Center and its partners have been working on the plans for Helix Park, a 37-acre campus expansion of TMC. As of this week, the first building has opened its doors to the public.

The TMC3 Collaborative Building officially opened today to a crowd of media, public officials, and health care executives. The institutional agnostic, 250,000-square-foot building will anchor Helix Park and house research initiatives from the four founding partners: Texas Medical Center, The University of Texas MD Anderson Cancer Center, Texas A&M University Health Science Center, and The University of Texas Health Science Center at Houston.

“Today, we lay the cornerstone of a new campus fully dedicated to streamlining the commercialization of life-changing innovations in medicine and technologies,” William McKeon, president and CEO of TMC, says at the event. “We are incredibly excited to both welcome our founding institutions and industry partners to the Collaborative Building and to invite the community to experience the Helix Park campus and its beautiful parks with a series of special events in the months ahead."

Established to be a place for academic institution collaboration, the building — designed by Boston-based Elkus Manfredi Architects — will have wet laboratories, office space, and event facilities. Two venture groups — Portal Innovations and the TMC Venture Fund — will also move into the building.

Each institution will bring in select programs and initiatives. MD Anderson will house two institutions within the new building, including the James P. Allison Institute focused on immunotherapy and the Institute for Data Science in Oncology.

"The future of life sciences in Houston is brighter than ever before as we come together to officially open the TMC3 Collaborative Building,” Dr. Peter WT Pisters, president of MD Anderson, says. “Our clinicians and scientists work daily to advance innovations in cancer research and care – all of which will be amplified in this new environment within Helix Park that further cultivates collaboration, connectivity, and creativity.”

UTHealth will move its Texas Therapeutics Institute into the facility.

“With a shared commitment to improving the health and well-being of individuals and communities, we are bringing together academics and industry to accelerate discovery and medical breakthroughs,” Dr. Giuseppe N. Colasurdo, president and Alkek-Williams Distinguished Chair at UTHealth Houston, says. “Through the Texas Therapeutics Institute — already a signature collaborative enterprise at UTHealth Houston — our world-renowned leaders in therapeutic antibody development will have the opportunity to work closely with other leading researchers in the Texas Medical Center, greatly enhancing our collective ability to translate discoveries and ideas into effective treatments.”

Texas A&M, which has worked with Houston Methodist to develop its engineering medical program, will operate its Texas A&M Health’s Institute of Biosciences and Technology in the new space.

“As we open this state-of-the-art facility, we’re opening the door to a new era of collaboration. This building signifies the dismantling of silos to deliver game-changing therapies for the toughest diseases impacting Texans and citizens worldwide,” said John Sharp, Chancellor of The Texas A&M University System. “Texas A&M Health’s Institute of Biosciences and Technology has long been a trailblazer in drug discovery, and now, in the heart of this resource-rich ecosystem of the Texas Medical Center, we’re taking it up a notch. By positioning our scientists near their peers and esteemed clinicians, we’re igniting a spark that will fuel innovation and forge dynamic research programs.”

The next aspect of Helix Park to deliver will be the Dynamic One, a 700,000-square-foot industry research facility. Several other buildings, including a hotel, residential tower, and mixed-use building, are expected to deliver over the next few years. The "spine" of the project is six linked green spaces, designed by landscape architect Mikyoung Kim, that form an 18.7-acre campus, which is shaped like a DNA helix, hence the project's name.

At the opening event, leaders discussed the annual impact of over $5.4 billion expected after the campus is completed, and the 23,000 permanent new jobs and 19,000 construction jobs anticipated from Helix Park.

"Texas truly is the home of innovation. Our energy innovations are legendary, as are our innovations in space," says Texas Governor Greg Abbott, naming several of the state's innovative accomplishments. "Long before all of this innovation we're seeing now, Texas was the home of the Texas Medical Center."

Mayor Sylvester Turner spoke to the importance of collaboration.

"Individually, you can do things very well. Collectively, you can be transformational," he says. "One thing about this city, collaboration is the key. When we play well together, and when we build an integrated, robust ecosystem, everyone wins. That's Houston, and that's the way we operate."

Texas A&M University will build a new facility near NASA's Johnson Space Center. Photo courtesy of JSC

Texas university to build $200M space institute in Houston

gig 'em

Texas A&M University's board of regents voted to approve the construction of a new institute in Houston that hopes to contribute to maintaining the state's leadership within the aerospace sector.

This week, the Texas A&M Space Institute got the greenlight for its $200 million plan. The announcement follows a $350 million investment from the Texas Legislature. The institute is planned to be constructed next to NASA’s Johnson Space Center in Houston.

“The Texas A&M Space Institute will make sure the state expands its role as a leader in the new space economy,” John Sharp, chancellor of the Texas A&M System, says in a news release. “No university is better equipped for aeronautics and space projects than Texas A&M.”

The new institute would build on A&M's expertise and resources to, according to the release, "make new discoveries, technological developments, health advances and workforce growth." Within its system, the university's space presence includes:

  • Four astronaut faculty members.
  • Scientists and engineers have participated in all NASA rover missions to Mars with two scientists active on NASA's Perseverance Rover Team.
  • More than 280 faculty and investigators are involved in space-related research.
  • Students, faculty and researchers are working on more than 300 space-related projects.
  • For the past five years, over 25 million per year in funding awards from NASA, other government agencies, and the commercial space industry.
  • Interdisciplinary space-related research across more than 12 colleges/schools within the Texas A&M University System universities.

Last summer, NASA and Texas A&M signed a Space Act Agreement, a general agreement to promote collaboration with the agency.

A new AI-optimized COVID screening device, a free response resource, and more — here's your latest roundup of research news. Image via Getty Images

These are the latest COVID-19-focused research projects happening at Houston institutions

research roundup

Researchers across the Houston area are working on COVID-19 innovations every day, and scientists are constantly finding new ways this disease is affecting humankind.

From a COVID breathalyzer to a new collaboration in Houston — here's your latest roundup of local coronavirus research news.

A&M System to collaborate on a COVID-19 breathalyzer

A prototype of the device will be used on the Texas A&M campus. Photo via tamu.edu

Researchers at Texas A&M University System are collaborating on a new device that uses artificial intelligence in a breathalyzer situation to detect whether individuals should be tested for COVID-19. The technology is being developed through a collaboration with Dallas-based company, Worlds Inc., and the U.S. Air Force.

The device is called Worlds Protect and a patient can use a disposable straw to blow into a copper inlet. In less than a minute, test results can be sent to the person's smartphone. Worlds Inc. co-founders Dave Copps and Chris Rohde envision Worlds Protect kiosks outside of highly populated areas to act as a screening process, according to a news release.

"People can walk up and, literally, just breathe into the device," says Rohde, president of Worlds Inc., in the release. "It's completely noninvasive. There's no amount of touching. And you quickly get a result. You get a yay or nay."

The university system has contributed $1 million in the project's development and is assisting Worlds Inc. with engineering and design, prototype building and the mapping of a commercial manufacturing process. According to the release, the plan was to test the prototypes will be tried out this fall on the Texas A&M campus.

"Getting tech innovations to market is one of our sweet spots," says John Sharp, chancellor of the Texas A&M System, in the release. "This breakthrough could have lasting impact on global public health."

Baylor College of Medicine researchers to determine cyclosporine’s role in treating hospitalized COVID-19 patients

BCM researchers are looking into the treatment effect of an existing drug on COVID-19 patients. Photo via BCM.edu

The Baylor College of Medicine has launched a randomized clinical trial to look into how the drug cyclosporine effects the prevention of disease progression in pre-ICU hospitalized COVID-19 patients. The drug has been used for about 40 years to prevent rejection of organ transplants and to treat patients with rheumatoid arthritis and psoriasis.

"The rationale is strong because the drug has a good safety profile, is expected to target the body's hyperimmune response to COVID and has been shown to directly inhibit human coronaviruses in the lab," says Dr. Bryan Burt, chief of thoracic surgery in the Michael E. DeBakey Department of Surgery at Baylor, says in a press release.

Burt initiated this trial and BCM is the primary site for the study, with some collaboration with Brigham and Women's. The hypothesis is that the drug will help prevent the cytokine storm that patients with COVID-19 experience that causes their health to decline rapidly, according to the release.

The study, which is funded by Novartis, plans to enroll 75 hospitalized COVID-19 patients at Baylor St. Luke's Medical Center who are not in the ICU. There will be an initial evaluation at six months but Burt expects to have the final study results in one year.

Rice launches expert group to help guide pandemic response

A new response team is emerging out of a collaboration led by Rice University. Photo courtesy of Rice

Rice University is collaborating with other Houston institutions to create the Biomedical Expert Panel, supported by Texas Policy Lab, to assist officials in long-term pandemic recovery.

"Not all agencies and decision-makers have an in-house epidemiologist or easy access to leaders in infectious disease, immunology and health communications," says Stephen Spann, chair of the panel and founding dean of the University of Houston College of Medicine, in a news release. "This panel is about equity. We must break out of our knowledge siloes and face this challenge together, with a commitment to inclusivity and openness."

The purpose of the panel is to be available as a free resource to health departments, social service agencies, school districts and other policymakers. The experts will help design efficient public health surveillance plans, advise on increasing testing capacity and access for underserved communities, and more.

"The precise trajectory of the local epidemic is difficult to predict, but we know that COVID-19 will continue to be a long-term challenge," says E. Susan Amirian, an epidemiologist who leads the TPL's health program, in the release. "Although CDC guidelines offer a good foundation, there is no one-size-fits-all approach when managing a crisis of this magnitude across diverse communities with urgent needs."

A&M's Research Integration Center, which will house data and act as an innovation hub for innovators and military specialists, is expected to be completed next fall. Photo via tamu.edu

Texas A&M University approves $60.3M for military innovation project

gig 'em

Texas A&M University is in the process of building a $200 million, multi-building facility just off its main campus in College Station and Bryan, Texas. As of this week, the project has fresh funds from the A&M Board of Regents to continue on with construction.

The board approved a $60.3 million projects at the George H.W. Bush Combat Development Complex, or BCDC, on the RELLIS Campus in Bryan, according to a press release from the university. According to a news release from the university, $22.5 million approved will go toward hypersonic and directed energy testing range called BAM — which stands for Ballistic, Aero-Optics, and Materials. At one kilometer long and two meters in diameter, BAM is expected to the largest enclosed hypersonic testing facility in the nation.

"There will be no other place like it in the world," says John Sharp, chancellor of the Texas A&M System, in the release.

BAM's construction is scheduled to begin in February — with completion by October 2022.

The other $37.8 million of the recent funds approved will go toward for a vehicle test track called the Innovation Proving Ground, or IPG. That's set to break ground in May 2021, and completion is expected a year later.

In addition to the construction at the BCDC, A&M's RELLIS Campus is also working on a few military innovation projects. Construction is currently underway on the Research Integration Center, or RIC, that will house all the data for the BCDC and act as a place to meet and collaborate for innovators and government personnel. The three-story innovation hub broke ground in October 2019 and is expected to be completed in the fall of 2021.

The complex is being supported by an initial $135 million investment from the state of Texas, the Texas A&M Engineering Experiment Station, and the Texas A&M University System. The U.S. Army Futures Command, or AFC) will invest up to $65 million over five years.

The plans come from a collaboration between the AFC, the U.S. Army Combat Capabilities Development Command Army Research Laboratory, other military branches, NASA, and other federal agencies, according to a release.

"Some universities talk about, 'Here's what we are going to do for you,'" says Sharp, in a release. "At Texas A&M, we ask, 'What do you want us to do for you?'"

Texas A&M's RELLIS campus sits about 10 miles down the road from the main campus. Photo via tamu.edu

Houston researchers are working to provide COVID-19 solutions amid the pandemic. Getty Images

These 5 Houston-area research institutions have bright minds at work to battle COVID-19

research roundup

Since even the early days of COVID-19's existence, researchers all over the world were rallying to find a cure or potential vaccine — which usually take years to make, test, and get approved.

Houston researchers were among this group to put their thinking caps on to come up with solutions to the many problems of the coronavirus. From the testing of existing drugs to tapping into tech to map the disease, here are some research projects that are happening in Houston and are emerging to fight the pandemic.

Baylor College of Medicine evaluating potential COVID-fighting drug

Human Body Organs (Lungs Anatomy)

Baylor College of Medicine has identified a drug that could potentially help heal COVID-19 patients. Photo via bcm.edu

While Baylor College of Medicine has professionals attacking COVID-19 from all angles, one recent discovery at BCM includes a new drug for treating COVID-caused pneumonia.

BCM researchers are looking into Tocilizumab's (TCZ), an immunomodulator drug, effect on patients at Baylor St. Luke's Medical Center and Harris Health System's Ben Taub Hospital.

"The organ most commonly affected by COVID-19 is the lung, causing pneumonia for some patients and leading to difficulty breathing," says Dr. Ivan O. Rosas, chief of the pulmonary, critical care and sleep medicine section at BCM, in a news release.

TCZ, which has been used to successfully treat hyperimmune responses in cancer patients being treated with immunotherapy, targets the immune response to the coronavirus. It isn't expected to get rid of the virus, but hopefully will reduce the "cytokine storm," which is described as "the hyper-immune response triggered by the viral pneumonia" in the release.

The randomized clinical trial is looking to treat 330 participants and estimates completion of enrollment early next month and is sponsored by Genentech, a biotechnology company.

Texas A&M University leads drug testing

A Texas A&M University researcher is trying to figure out if an existing vaccine has an effect on COVID-19. Screenshot via youtube.com

A researcher from Texas A&M University is working with his colleagues on a short-term response to COVID-19. A vaccine, called BDG, has already been deemed safe and used for treatment for bladder cancer. BDG can work to strengthen the immune system.

"It's not going to prevent people from getting infected," says Dr. Jeffrey D. Cirillo, a Regent's Professor of Microbial Pathogenesis and Immunology at the Texas A&M Health Science Center, in a news release. "This vaccine has the very broad ability to strengthen your immune response. We call it 'trained immunity.'"

A&M leads the study in partnership with the University of Texas MD Anderson Cancer Center and Baylor College of Medicine in Houston, as well as Harvard University's School of Public Health and Cedars Sinai Medical Center in Los Angeles.

Texas A&M Chancellor John Sharp last week set aside $2.5 million from the Chancellor's Research Initiative for the study. This has freed up Cirillo's team's time that was previously being used to apply for grants.

"If there was ever a time to invest in medical research, it is now," Sharp says in the release. "Dr. Cirillo has a head start on a possible coronavirus treatment, and I want to make sure he has what he needs to protect the world from more of the horrible effects of this pandemic."

Currently, the research team is recruiting 1,800 volunteers for the trial that is already underway in College Station and Houston — with the potential for expansion in Los Angeles and Boston. Medical professionals interested in the trial can contact Gabriel Neal, MD at gneal@tamu.edu or Jeffrey Cirillo, PhD at jdcirillo@tamu.edu or George Udeani, PharmD DSc at udeani@tamu.edu.

"This could make a huge difference in the next two to three years while the development of a specific vaccine is developed for COVID-19," Cirillo says in the release.

Rice University is creating a COVID-19 map

Researchers at Rice University's Center for Research Computing's Spatial Studies Lab have mapped out all cases of COVID-19 across Texas by tapping into public health data. The map, which is accessible at coronavirusintexas.org, also identifies the number of people tested across the state, hospital bed utilization rate, and more.

The project is led by Farès el-Dahdah, director of Rice's Humanities Research Center. El-Dahdah used open source code made available by ESRI and data from the Texas Department of State Health Services and Definitive Healthcare.

"Now that the Texas Division of Emergency Management released its own GIS hub, our dashboard will move away from duplicating information in order to correlate other numbers such as those of available beds and the potential for increasing the number of beds in relation to the location of available COVID providers," el-Dahdah says in a press release.

"We're now adding another layer, which is the number of available nurses," el-Dahdah continues. "Because if this explodes, as a doctor friend recently told me, we could be running out of nurses before running out of beds."


Texas Heart Institute is making vaccines more effective

A new compound being developed at Texas Heart Institute could revolutionize the effect of vaccines. Photo via texasheart.org

Molecular technology coming out of the Texas Heart Institute and 7 HIlls Pharma could make vaccines — like a potential coronavirus vaccine — more effective. The oral integrin activator has been licensed to 7 Hills and is slated to a part of a Phase 1 healthy volunteer study to support solid tumor and infectious disease indications in the fall, according to a press release.

The program is led by Dr. Peter Vanderslice, director of biology at the Molecular Cardiology Research Laboratory at Texas Heart Institute. The compound was first envisioned to improve stem cell therapy for potential use as an immunotherapeutic for certain cancers.

"Our research and clinical colleagues are working diligently every day to advance promising discoveries for at risk patients," says Dr. Darren Woodside, co-inventor and vice president for research at the Texas Heart Institute, in the release. "This platform could be an important therapeutic agent for cardiac and cancer patients as well as older individuals at higher risk for infections."

University of Houston's nanotech health monitor

UH researchers have developed a pliable, thin material that can monitor changes in temperature. Photo via uh.edu

While developed prior to the pandemic, nanotechnology out of the University of Houston could be useful in monitoring COVID patients' temperatures. The material, as described in a paper published by ACS Applied Nano Materials, is made up of carbon nanotubes and can indicate slight body temperature changes. It's thin and pliable, making it ideal for a wearable health tech device.

"Your body can tell you something is wrong before it becomes obvious," says Seamus Curran, a physics professor at the University of Houston and co-author on the paper, in a news release.

Curran's nanotechnology research with fellow researchers Kang-Shyang Liao and Alexander J. Wang, which also has applications in making particle-blocking face masks, began almost 10 years ago.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston Technology Center founder dies, leaves legacy of innovation

saying goodbye

The Houston innovation ecosystem is mourning the loss of one of its early leaders, Paul Frison, who died on September 5. He was 87.

A long-time Houston businessman, Frison founded the Houston Technology Center in 1999 and served as its CEO and president. The organization evolved into Houston Exponential several years ago. Frison remained active within Houston innovation until 2020.

“Paul Frison was a visionary and energetic leader who always presented a positive outlook on what the Houston technology entrepreneurship community could become," Brad Burke, associate vice president for industry and new ventures at Rice University's Office of Innovation, remembers. "He was one of the pioneers in the community who established the Houston Technology Center as one of the early leaders of the Houston ecosystem. I admired how he helped launch the ecosystem and created the platform for many others to build upon.”

Prior to HTC, he served in various executive roles at American Hospital Supply, LifeMark, ComputerCraft, and LifeCell, spending the last 50 of his years in Houston. Born in Glendale, California, he served in the Unites States Coast Guard.

Blair Garrou, co-founder and managing director of Mercury Fund, says Frison was his first boss and mentor in the tech and entrepreneurship sector.

“When people look back to how the Houston tech community was founded, it starts with Paul Frison," Garrou says. "Paul had run multiple companies and I was lucky to have him as CEO when I worked for him at the Houston Technology Center. He quickly became a mentor, and over time, a good friend and confidant. I have Paul to thank for launching my career in tech and venture capital.

"My favorite quote of Paul’s was, 'Do not confuse effort with results,'” Garrou continues. "Despite his results-driven work ethic – which was legendary — Paul was also deeply-rooted in family and faith, and has been a role model for me over my entire professional life.”

He is preceded in death by his wife, Barbara, and his grandson, Christian David Elders. He is survived by his daughters Maryanne Elders and Jill Cortez and their families, including grandchildren Matthew Elders, Laney Elders, Max Cortez, Jake Cortez, and Sofie Cortez.

A celebration of life will be held for Frison on September 16 at 1 pm at Second Baptist Church, with a reception following in the Deacon’s Parlor. More details are available online. In lieu of flowers, Frison's wishes were for for donations to Second Baptist Church to be made in his honor.

Artist collective brings carbon-absorbing murals to Houston

WHEN FINE ART MEETS FRESH AIR

Anthony Rose, the CEO of creative agency United By Design, is on a mission to brighten Houston’s urban spaces and improve the city’s air quality one carbon-absorbing mural at a time.

Rose originally founded United By Design, or UXD, in 2019 to connect muralists like himself and commercial businesses seeking to beautify their spaces and form brand identities. After creating vibrant murals for Lockhart Elementary School, the Houston Astros, and Smoothie King, Rose expanded UXD’s vision to include environmental sustainability in their artistic collaborations in 2022.

“This city’s vibrant art scene and growing focus on sustainability makes it an ideal location for our projects,” Rose says. “We’re not just creating eco-friendly murals, we’re reimagining how art can actively contribute to environmental solutions.”

In search of ecologically-conscious paints, Rose formed a partnership with Spain-based, natural paint company Graphenstone. Rose says he was drawn to the company’s eponymous Graphenstone coating because of its nontoxic ingredients and exclusively uses the product for UXD’s carbon-absorbing murals.

"Between Land and Sky" by artist David Maldonado was UXD's first carbon-absorbing painting. Photo courtesy of Dario DeLeon and Tommy Valdez

The Graphenstone coating consists of a limestone base which goes through a process called photocatalysis, during which carbon dioxide from the atmosphere is absorbed into the surface, and is then sealed in with graphene, a thin layer of carbon atoms. The murals absorb carbon dioxide throughout the coat’s drying process which typically takes 30 days.

“Each of our murals absorbs about 1600 grams of CO2 during that curing process which is the equivalent daily absorption of about 33 growing trees,” Rose explains.

UXD’s largest carbon-absorbing mural to date is a floor-to-ceiling panorama in downtown Houston’s historic Mellie Esperson building, home to the company’s new creative hub. Painted by Houston-born artist Emily Ding, the mural is a tribute to the establishment’s namesake: an innovative, early 20th century entrepreneur who constructed the opulent building.

"Future's Past" by Emily Ding in partnership with UXD tells the story of the Mellie Esperson building. Photo courtesy of Dario DeLeon

Rose says UXD plans to expand their carbon-absorbing murals project in collaboration with more local artists and establishments, while creating an artist-in-residency program themed around sustainability. Though Rose acknowledges in the grand scheme of carbon pollution these murals are not a silver bullet, he says the non-toxic paints are encouraging conversations about how artists can be conservation-minded.

“We’re trying to figure out how art as a messaging tool can help break down scientific data, a language not many people practice daily, can break down barriers and help bridge the gap to a more intuitive knowledge of sustainability,” Rose says. “We’re bringing the community together, helping them feel empowered, and giving them actionable information to help them live more sustainable lives.”

Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a health tech innovator, an investor, and a startup CEO.

Jon Nordby, managing director of Anthropy Partners

Jon Nordby's career has been focused on cultivating a culture for innovation, and now he's focused on human potential technology opportunities. Photo courtesy

In his role overseeing startup accelerators for MassChallenge, Jon Nordby started noticing one industry vertical stood out in terms of success and opportunities: Human potential. Now, Nordby is a founding member of an investment firm looking for those opportunities.

Nordby, who served in various leadership roles at MassChallenge — including managing director and head of ecosystems — said he started realizing the opportunities within the organization's space and sports tech programs.

"What we realized over a couple of years running the program was that sports tech as a theme was too limiting," Nordby says on the Houston Innovators Podcast. "We were finding really great technologies, but we were limited at the market size of teams and leagues to deploy those technologies."

"Over the course of that program, we found that the things that were related more to human health and performance tended to out perform all of the other things related to sports tech — like media, entertainment, gambling," Nordby continues. "Still really great markets for those technologies, but we found a lot more traction for human performance." Read more.

Benjamin Musher, professor at Baylor College of Medicine and medical director of medical oncology at the Duncan Cancer Center McNair Campus

The new center is specifically designed to allow patients to be on the cutting edge of testing brand-new therapies that could save their lives. Photo via BCM

Cancer treatment in Houston just became even more promising — and forward-thinking.

Phase 1 clinical trials are necessary to prove the efficacy in humans of treatments that have appeared promising in lab trials. In the name of cancer-fighting innovation, Baylor College of Medicine’s Dan L. Duncan Comprehensive Cancer Center has launched the Albert and Margaret Alkek Foundation Center for Experimental Therapeutics.

The new center is specifically designed to allow patients to be on the cutting edge of testing brand-new therapies that could save their lives.

“Clinical trials are critical for advancing the field of oncology and improving outcomes for cancer patients. Phase 1 trials are the first step in bringing innovative therapies to the clinic,” says Dr. Benjamin Musher, Barry S. Smith endowed professor at Baylor and medical director of medical oncology at the Duncan Cancer Center McNair Campus, in a news release. “Our new program will build on the success of previous phase 1 trials at Baylor and provide robust infrastructure to offer more clinical trial opportunities to our patients.” Read more.

Mark Semmelbeck, founder and CEO of A Better Meal

A Better Meal — a new app from a Houston founder — gives you all the tools you need to make healthier food choices. Photo courtesy

After many years of living to eat, a large swath of American society is now facilitating a seismic shift to the healthier alternative, eating to live.

But here’s the rub: eating healthy is confusing, time consuming and, unfortunately, oftentimes pricey.

So, anyone that can come in and cut through the healthy eating machine can carve out a necessary niche in the marketplace.

Enter Houstonian Mark Semmelbeck, founder and CEO of A Better Meal, a platform created to help busy families plan healthy meals easier and to make gradual improvements to their health and well-being.

“My vision is to use rapidly expanding AI technology together with the knowledge and wisdom of an active community to take the stress out of meal planning and improving nutrition,” says Semmelbeck, a seasoned oil and gas executive with over 30 years of experience in founding companies. “While developing the technology for the app, my daughter gave me two beautiful grandkids who both have significant food allergies. Combine that with the fact I now have five cardiac stents and the significance of eating well while paying attention to the details has only grown in importance.” Read more.